0 Immunotherapy packages match your search

What immunotherapy is and who it is for

Immunotherapy helps your own immune system recognise and attack cancer cells. The most widely used type, checkpoint inhibitors, releases natural 'brakes' that tumours exploit to hide from immune attack. Other approaches include monoclonal antibodies, therapeutic vaccines and, for certain blood cancers, advanced cell therapies. It is a fundamentally different tool from chemotherapy: rather than directly poisoning dividing cells, it changes how your immune system behaves.

Immunotherapy is not suitable for every cancer or every patient. Its use depends on the tumour type and, increasingly, on biomarkers — molecular tests (such as PD-L1 expression or markers of high mutation load) that predict whether the immune system is likely to respond. A medical oncologist decides whether it fits your case, alone or combined with other treatments. Because it is given over months and can cause delayed immune side effects, continuity of care is especially important.

Be cautious of clinics marketing unproven 'immune-boosting' therapies as cancer cures. Genuine immunotherapy is specific, evidence-based and biomarker-guided, and a reputable centre will explain exactly which approved agent it proposes and why.

Types of immunotherapy and how they differ

Checkpoint inhibitors are the most common form and are approved for a growing list of cancers; they are given by infusion every few weeks. Monoclonal antibodies target specific proteins on cancer cells, sometimes flagging them for immune destruction or delivering a payload directly. Therapeutic cancer vaccines aim to train the immune system against tumour-specific targets. Cell therapies, such as CAR-T for certain blood cancers, re-engineer a patient's own immune cells and are highly specialised, intensive treatments delivered only at select centres.

The key differences for patients are eligibility, intensity and setting. Checkpoint inhibitors are often outpatient infusions with a distinctive side-effect profile. Cell therapies are far more involved, requiring specialist inpatient care and close monitoring for serious reactions. The right option, if any, is dictated by your diagnosis and biomarkers.

This is an area where evidence moves quickly and marketing can outrun proof. Insist on knowing whether a proposed therapy is approved for your specific cancer and what data supports it. A trustworthy oncologist distinguishes clearly between standard-of-care immunotherapy and experimental options.

What is included and what it costs

The dominant cost in immunotherapy is usually the drug itself, which can be expensive and is given repeatedly over many months. A meaningful quote should specify the exact agent, the dose and interval, the expected duration, the biomarker testing needed to confirm eligibility, the monitoring scans and bloods, and the management of immune-related side effects, which can require additional drugs and admissions.

As a broad orientation only, a full course of checkpoint-inhibitor immunotherapy can run into the tens of thousands of euros over its duration, sometimes considerably more depending on the molecule and how long treatment continues. Cell therapies are substantially more costly and specialised. These are wide ranges, and any quote should be tied to your specific drug and plan rather than a headline figure.

Ask how long treatment is expected to last, how response is assessed, and how the cost of managing side effects is handled, since immune reactions can be unpredictable. A responsible centre is transparent about the open-ended nature of some immunotherapy courses.

Choosing a centre and an oncologist

Immunotherapy requires a centre experienced in recognising and managing immune-related side effects, which can affect almost any organ and sometimes appear weeks after a dose. Look for hospital accreditation such as JCI and a board-certified medical oncologist, and ask specifically how the team handles immune toxicities — do they have clear protocols, access to relevant specialists, and out-of-hours cover?

Biomarker testing capability is a marker of quality. A serious centre confirms eligibility with proper molecular testing rather than offering immunotherapy indiscriminately. Ask what test will be used, how it informs the choice of drug, and whether the proposed therapy is approved for your tumour type.

Continuity is critical here because side effects can surface after you have travelled home. Confirm the centre will document exactly which agent and doses you received and share that with your home team, and that your home clinicians will know how to recognise and treat immune-related reactions.

Treatment rhythm, side effects and recovery

Checkpoint-inhibitor immunotherapy is typically given as an outpatient infusion every two to six weeks over many months. Many patients tolerate it well and continue normal activities, but it has a distinctive side-effect profile: because it activates the immune system, it can cause inflammation in healthy organs — skin, gut, lungs, liver, hormone glands and others — known as immune-related adverse events. These can be mild or serious, and importantly can appear weeks or even months after a dose, sometimes after treatment has stopped.

This delayed-toxicity pattern is the defining planning fact for anyone considering immunotherapy abroad. A side effect may not declare itself until you are back home, so your home team must know precisely what you received and how to manage immune reactions, which often involve specific steroid or immune-suppressing protocols.

For most patients, a shared-care model makes sense: confirm eligibility and start treatment with the specialist centre, but ensure ongoing infusions or surveillance can be safely continued and monitored at home with full records in hand.

Risks and what if something goes wrong

The main risk of immunotherapy is immune-related adverse events — the same immune activation that fights the cancer can attack healthy organs. Most are manageable when caught early, but some are serious and a few can be life-threatening if missed, particularly inflammation of the lungs, bowel, liver or hormone glands. Early recognition and prompt treatment, often with steroids, are what make these safe.

The travel-specific danger is that these effects may emerge after you return home, where clinicians who did not deliver the treatment must manage them. This makes documentation and second opinions non-negotiable. Get an independent view before committing, and verify your home team will accept the records and knows the relevant management protocols.

Ask the centre, before you travel, what its pathway is for immune toxicities both during treatment and after discharge. Keep a clear record of every dose and date, and carry information that lets any clinician quickly understand you are on immunotherapy and what that implies.

Frequently asked

Related searches